CEO Torsten Freltoft presents AcouSort's opportunities in cell therapy and diagnostics at LSX Nordic Congress on October 10
AcouSort is an innovative medical technology company developing critical components for instrumentation used in the diagnostics, analytics, and cell therapy processing markets. The company is in early commercial phase with continuously strengthened positions in the company's focus areas – diagnostics, cell therapy and innovation.
The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conference for the Nordic region. It has been connecting life science and healthcare industry leaders with international investment and strategic partners to further the growth, development and internationalization of Nordic life science and healthcare innovation since 2018. AcouSort’s presentation will take place during the Med/Health-tech Showcase steam on Tuesday 10th October at 16:30.
"I have presented AcouSort many times, but it has never been more stimulating to do so than now. The Company is in a very exciting phase with several interesting research and development collaborations with the potential to lead to OEM agreements where our unique technology is integrated into various systems for diagnostics and production of cells for cell therapies," says Torsten Freltoft, AcouSort’s CEO.
Register here: https://www.lsxleaders.com/lsx-nordic-congress
FOR FURTHER INFORMATION ON ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank.